BioVersys brings new partner on board

The Basel-based pharmaceutical company BioVersys AG and the US company Aptuit will collaborate to develop novel approaches to treat serious infections from Gram-negative pathogens. Their goal is to combat antibiotic resistance.

BioVersys AG and Aptuit will collaborate. (generic image)

BioVersys AG specialises in the development of small molecules interfering with transcriptional regulation of bacteria, thus addressing novel targets to overcome the threat caused by antibiotic resistance.

The Basel-based company will now collaborate with Aptuit to identify novel approaches to treat serious infections from Gram-negative bacteria. According to a statement announcing the collaboration, BioVersys brings “one of its most innovative targets focused on Gram-negative pathogens” to their joint effort.

Headquartered in the US state of Connecticut, the pharmaceutical services provider Aptuit will provide its expertise in integrated infectious disease drug discovery to the collaboration, complementing BioVersys’ scientific platform in the transcriptional regulator area.

"I am delighted that Aptuit has been selected to support the development of Bioversys’ innovative project pipeline,” said Jonathan Goldman, CEO of Aptuit. “As a Partner Research Organization we are fully committed to leveraging our expertise in the renewed challenge associated to the discovery of new effective therapeutics against MDR Gram-negative pathogens”.

Recommend us
How should we contact you?

Premium Partner

Strategic partners

Institutional partner

Official program